H. Ghanem, H. Kantarjian, M. Ohanian, and E. Jabbour, The role of clofarabine in acute myeloid leukemia, Leukemia & Lymphoma, vol.108, issue.1, pp.688-698, 2013.
DOI : 10.1111/j.1600-0609.2011.01703.x

J. Kline and R. Larson, Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review, Expert Opinion on Pharmacotherapy, vol.4, issue.15, pp.2711-2718, 2005.
DOI : 10.1056/NEJM199808273390907

J. Middeke, R. Herbst, and S. Parmentier, Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial, Leukemia, vol.30, issue.2, pp.261-267, 2016.
DOI : 10.1016/j.leukres.2010.09.002

H. Kantarjian, S. Jeha, V. Gandhi, M. Wess, and S. Faderl, Clofarabine: Past, present, and future, Leukemia & Lymphoma, vol.108, issue.10, pp.1922-1930, 2007.
DOI : 10.1002/cncr.22508

P. Chevallier, M. Labopin, and G. Socie, Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial, Haematologica, vol.99, issue.9, pp.1486-1491, 2014.
DOI : 10.3324/haematol.2014.108563
URL : https://hal.archives-ouvertes.fr/hal-01325352

N. Krivoy, E. Hoffer, Y. Lurie, Y. Bentur, and J. Rowe, Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children, Current Drug Safety, vol.3, issue.1, pp.60-66, 2008.
DOI : 10.2174/157488608783333899

J. Russell and S. Kangarloo, Therapeutic Drug Monitoring of Busulfan in Transplantation, Current Pharmaceutical Design, vol.14, issue.20, pp.1936-1949, 2008.
DOI : 10.2174/138161208785061382

S. Almog, D. Kurnik, and A. Shimoni, Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination, Biology of Blood and Marrow Transplantation, vol.17, issue.1, pp.117-123, 2011.
DOI : 10.1016/j.bbmt.2010.06.017

H. Dohner, E. Estey, and S. Amadori, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2010.
DOI : 10.1182/blood-2009-07-235358

M. Mohty, W. Jacot, and C. Faucher, Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen, Leukemia, vol.17, issue.11, pp.2168-2177, 2003.
DOI : 10.1038/sj.leu.2403105

E. Brissot, P. Chevallier, and T. Guillaume, Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors, Bone Marrow Transplantation, vol.91, issue.4, pp.786-788, 2010.
DOI : 10.1038/bmt.2008.231

F. Malard, R. Szydlo, and E. Brissot, Impact of Cyclosporine-A Concentration on the Incidence of Severe Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.16, issue.1, pp.28-34, 2010.
DOI : 10.1016/j.bbmt.2009.08.010

Y. Kanda, Investigation of the freely available easy-to-use software ???EZR??? for medical statistics, Bone Marrow Transplantation, vol.48, issue.3, pp.452-458, 2013.
DOI : 10.1200/JCO.2007.12.9866

H. Fung, A. Stein, and M. Slovak, A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome, Biology of Blood and Marrow Transplantation, vol.9, issue.12, pp.766-771, 2003.
DOI : 10.1016/j.bbmt.2003.08.004

C. Schmid, M. Schleuning, and M. Hentrich, High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission, Bone Marrow Transplantation, vol.20, issue.8, pp.721-727, 2008.
DOI : 10.1038/sj.bmt.1705965

C. Schmid, M. Schleuning, and J. Tischer, Early allo-SCT for AML with a complex aberrant karyotype???results from a prospective pilot study, Bone Marrow Transplantation, vol.75, issue.1, pp.46-53, 2012.
DOI : 10.1182/blood-2002-12-3714

P. Hemmati, T. Terwey, and I. Na, Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome, European Journal of Haematology, vol.27, issue.6, pp.498-506, 2015.
DOI : 10.1111/ejh.12522

M. Mohty, F. Malard, and D. Blaise, Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: Results of a multicenter prospective phase 2 trial, Cancer, vol.117, issue.4, pp.562-569, 2015.
DOI : 10.1002/cncr.29087

M. Mohty, F. Malard, and B. Savani, High-Dose Total Body Irradiation and Myeloablative Conditioning before Allogeneic Hematopoietic Cell Transplantation: Time to Rethink?, Biology of Blood and Marrow Transplantation, vol.21, issue.4, pp.620-624, 2015.
DOI : 10.1016/j.bbmt.2014.09.010
URL : http://dx.doi.org/10.1016/j.bbmt.2014.09.010

D. Niederwieser, M. Maris, and J. Shizuru, Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases, Blood, vol.101, issue.4, pp.1620-1629, 2003.
DOI : 10.1182/blood-2002-05-1340

N. Bejanyan, D. Weisdorf, and B. Logan, Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study, Biology of Blood and Marrow Transplantation, vol.21, issue.3, pp.454-459, 2015.
DOI : 10.1016/j.bbmt.2014.11.007

C. Schmid, M. Labopin, and A. Nagler, Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation, Blood, vol.119, issue.6, pp.1599-1606, 2012.
DOI : 10.1182/blood-2011-08-375840

M. Liga, E. Triantafyllou, and M. Tiniakou, High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen, Biology of Blood and Marrow Transplantation, vol.19, issue.1, pp.75-81, 2013.
DOI : 10.1016/j.bbmt.2012.07.021

O. Goodyear, M. Dennis, and N. Jilani, Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML), Blood, vol.119, issue.14, pp.3361-3369, 2012.
DOI : 10.1182/blood-2011-09-377044

G. Schiller, P. Tuttle, and P. Desai, Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD???Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation, Biology of Blood and Marrow Transplantation, vol.22, issue.6, pp.982-990, 2016.
DOI : 10.1016/j.bbmt.2016.01.013

C. Kanakry, E. Fuchs, and L. Luznik, Modern approaches to HLA-haploidentical blood or marrow transplantation, Nature Reviews Clinical Oncology, vol.5, issue.1, pp.10-24, 2016.
DOI : 10.1182/blood-2007-03-082933
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695979